Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer

· 2021-04-23

The FOXM1 transcription factor is an oncoprotein and a top biomarker of poor prognosis in human cancer. Overexpression and activation of FOXM1 is frequent in high-grade serous carcinoma (HGSC), the most common and lethal form of human ovarian cancer, and is linked to copy number gains at chromosome 12p13.33. We show that FOXM1 is co-amplified and co-expressed with RHNO1 , a gene involved in the ATR-Chk1 signaling pathway that functions in the DNA replication stress response. We demonstrate that FOXM1 and RHNO1 are head-to-head (i.e., bidirectional) genes (BDG) regulated by a bidirectional promoter (BDP) (named F/R-BDP). FOXM1 and RHNO1 each promote oncogenic phenotypes in HGSC cells, including clonogenic growth, DNA homologous recombination repair, and poly-ADP ribosylase inhibitor resistance. FOXM1 and RHNO1 are one of the first examples of oncogenic BDG, and therapeutic targeting of FOXM1/RHNO1 BDG is a potential therapeutic approach for ovarian and other cancers.

Journal
eLife
Funding

NCI NIH HHS

F99 CA212470

NCI NIH HHS

P30 CA036727

NCI NIH HHS

P50 CA228991

NCI NIH HHS

T32 CA009476

National Institutes of Health

P30CA036727

Rivkin Center for Ovarian Cancer

2018 Kirwin-Hinton Family Bridge Funding Award

University of Nebraska Medical Center

National Institutes of Health

T32CA009476

National Institutes of Health

F99CA212470

National Institutes of Health

P50CA228991